• Aliyah Aliyah
  • Emilia Utomo
  • Andi Dian Permana Faculty of Pharmacy, Universitas Hasanuddin, Makassar
  • Ernawati


Objective:The aim of this study was to develop liquisolid formulation of propranolol hydrochloride to obtain improved sustained release profile by varying the ratio of liquid vehicles.

Methods:In this study, propranolol hydrochloride (PPH) was dispersed in the combination of propylene glycol and polysorbate 80, as liquid vehicle, with different ratios. Eudragit®RL and Aerosil®were used as carrier and coating materials, respectively, to produce a dry and free-flowing powder. In addition, HPMC was used to amplify the retardation effect. The prepared formulations were evaluated for its physicochemical properties including loss on drying, flow rate, and angle of repose calculation, drug content analysis, FT-IR spectroscopy, as well as dissolution studies. The obtained dissolution profiles were subsequently fitted to the mathematical model in order to determine the drug kinetics.

Results:The results show all formulations performed dry and free-flowing granules containing PPH in the range of 7-9%.  Furthermore, all the prepared formulations were able to sustain the drug release for the total of 8 hours in two different dissolution media, namely simulated gastric fluid and simulated intestinal fluid. F4 containing propylene glycol and polysorbate 80 (1:2) possessed the lowest drug release rate. It was also obtained that F1 and F3 followed first-order kinetics while F2, F4, and F5 complied with Higuchi model.

Conclusions:Overall, there was no difference in all the dissolution profiles based on the calculation of the difference and similarities factor.

Keywords: liquisolid granules, propranolol hydrochloride, sustained release


[1] Bose S, Kaur A, Sharma SK. a Review on Advances of Sustained Release Drug Delivery System. Int Res J Pharm. 2013;4(6):1–5.
[2] Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices. Int J Pharm. 2008;362(1–2):102–8.
[3] Gupta M, Brijesh R. A review on: sustained release technology. Int J Ther Appl. 2012;8(1):18–23.
[4] Badadhe S, Gawali V, Bhalsing M, Jadhav B. Sustained release dosage forms: An overview. Int J Innov Pharm Sci Res. 2016;4(12):1194–211.
[5] N.P. K, M.T. S, D.H. S, P.K. S. A review on liquisolid systems. J Drug Deliv Ther. 2014;4(3):25–31.
[6] Pawar JD, Jagtap RS, Doijad RC, Pol S V, Desai JR, Jadhav V V, et al. Liquisolid Compacts: a Promising Approach for Solubility Enhancement. J Drug Deliv Ther. 2017;7(4):6–11.
[7] Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from liquisolid systems: Speed it up, slow it down. Expert Opin Drug Deliv. 2011;8(2):191–205.
[8] Sweetman SC, editor. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.
[9] Yadav A, Jain DK. Formulation development and characterization of propranolol hydrochloride microballoons for gastroretentive floating drug delivery. African J Pharm Pharmacol. 2011;5(15):1801–10.
[10] Shah RB, Tawakkul MA, Khan MA. Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech. 2008;9(1):250–8.
[11] Holowka EP, Bhatia SK. Controlled Release Systems. In: Drug Delivery: Materials Design and Clinical Perspective. 2014. p. 8–62.
[12] Permana AD, Paredes AJ, Volpe-Zanutto F, Anjani QK, Utomo E, Donnelly RF. Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis. Eur J Pharm Biopharm. 2020;154(April):50–61.
[13] Permana AD, Tekko IA, McCrudden MTC, Anjani QK, Ramadon D, McCarthy HO, et al. Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. J Control Release. 2019;316(July):34–52.
[14] Permana AD, McCrudden MTC, Donnelly RF. Enhanced intradermal delivery of nanosuspensions of antifilariasis drugs using dissolving microneedles: A proof of concept study. Pharmaceutics. 2019;11(7):1–22.
[15] Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.
[16] Lu M, Xing H, Jiang J, Chen X, Yang T, Wang D, et al. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci. 2017;12(2):115–23.
[17] Sahoo J, Murthy PN, Biswal S, Sahoo SK, Mahapatra AK. Comparative study of propranolol hydrochloride release from matrix tablets with Kollidon®SR or hydroxy propyl methyl cellulose. AAPS PharmSciTech. 2008;9(2):577–82.
[18] Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. Sixth. London: Pharmaceutical Press; 2009.
[19] Balaji A, Umashankar MS, Kavitha B. Liquisolid technology- A latest review. Int J Appl Pharm. 2014;6(1):11–9.
[20] The United States Pharmacopeial Convention. USP 35. Vol. 35, U.S.Pharmacopoeia. 2012. 801–804 p.
[21] Chaturvedi K, Umadevi S, Vaghani S. Floating matrix dosage form for propranolol hydrochloride based on gas formation technique: Development and in vitro evaluation. Sci Pharm. 2010;78(4):927–39.
[22] Hernawan, Nurhayati S, Nisa K, Indrianingsih AW, Darsih C, Kismurtono M. Formulation and in vitro study of propranolol hydrochloride controlled release from carboxymethyl chitosan-based matrix tablets. Indones J Chem. 2013;13(3):242–7.
[23] Shoaib MH, Tazeen J, Merchant HA, Yousuf RI. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak J Pharm Sci. 2006;19(2):119–24.
[24] Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2012;64(SUPPL.):163–74.
[25] Adibkia K, Shokri J, Barzegar-Jalali M, Solduzian M, Javadzadeh Y. Effect of solvent type on retardation properties of diltiazem HCl form liquisolid tablets. Colloids Surfaces B Biointerfaces. 2014;113:10–4.
[26] Wójcik-Pastuszka D, Krzak J, Macikowski B, Berkowski R, Osi?ski B, Musia? W. Evaluation of the release kinetics of a pharmacologically active substance from model intra-articular implants replacing the cruciate ligaments of the knee. Materials (Basel). 2019;12(8).
[27] Paarakh MP, Jose PANI, Setty CM, Peter G V. Release Kinetics – Concepts and Applications. Int J Pharm Res Technol. 2019;8(1):12–20.
[28] Gouda R, Baishya H, Qing Z. Application of Mathematical Models in Drug Release Kinetics of Carbidopa and Levodopa ER Tablets. J Dev Drugs. 2017;06(02):1–8.
6 Views | Downloads
How to Cite
Aliyah, A., Utomo, E., Permana, A. D., & Ernawati. (2021). DEVELOPMENT OF LIQUISOLID FORMULATION FOR IMPROVED SUSTAINED RELEASE OF PROPRANOLOL HYDROCHLORIDE. International Journal of Applied Pharmaceutics, 13(2). Retrieved from
Original Article(s)